{
    "clinical_study": {
        "@rank": "68958", 
        "arm_group": [
            {
                "arm_group_label": "Telmisartan 80mg & Rosuvastatin 20mg", 
                "arm_group_type": "Experimental", 
                "description": "PO, Once Daily, 8 weeks"
            }, 
            {
                "arm_group_label": "Telmisartan 80mg & Rosuvastatin 10mg", 
                "arm_group_type": "Experimental", 
                "description": "PO, Once Daily, 8weeks"
            }, 
            {
                "arm_group_label": "Telmisartan placebo & Rosuvastatin 20mg", 
                "arm_group_type": "Active Comparator", 
                "description": "PO, Once Daily, 8 weeks"
            }, 
            {
                "arm_group_label": "Telmisartan Placebo & Rosuvastatin 10mg", 
                "arm_group_type": "Active Comparator", 
                "description": "PO, Once Daily, 8 weeks"
            }, 
            {
                "arm_group_label": "Telmisartan 80mg & Rosuvastatin placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "PO, Once Daily, 8 weeks"
            }, 
            {
                "arm_group_label": "Telmisartan placebo & Rosuvastatin placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "PO, Once Daily, 8 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "To identify efficacy and safety of Telmisartan/Rosuvastatin co-administration in\n      hyperlipidemia control in hypertensive patients with hyperlipidemia compared to each\n      monotherapy."
        }, 
        "brief_title": "Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia", 
        "condition": [
            "Hypertension", 
            "Hyperlipidemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hyperlipidemias", 
                "Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed Informed Consent\n\n          -  Men and women >18 years of age\n\n          -  Subject who has one of 3 conditions classifed by Cardiovascular Risk Factors, 10-Year\n             Risk, Blood Pressure, LDL-C, Coronary Artery Disease and Equivalent\n\n        Exclusion Criteria:\n\n          -  Female who are pregnant, breastfeeding, or of childbearing potential, unwilling to\n             practice adequate contraception throughout the study,.\n\n          -  Other exclusions applied"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "310", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02087540", 
            "org_study_id": "ID_Telotan_1203"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Telmisartan 80mg & Rosuvastatin 20mg", 
                    "Telmisartan 80mg & Rosuvastatin 10mg", 
                    "Telmisartan 80mg & Rosuvastatin placebo"
                ], 
                "intervention_name": "Telmisartan 80mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Telmisartan 80mg & Rosuvastatin 20mg", 
                    "Telmisartan placebo & Rosuvastatin 20mg"
                ], 
                "intervention_name": "Rosuvastatin 20mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Telmisartan 80mg & Rosuvastatin 10mg", 
                    "Telmisartan Placebo & Rosuvastatin 10mg"
                ], 
                "intervention_name": "Rosuvastatin 10mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Telmisartan placebo & Rosuvastatin 20mg", 
                    "Telmisartan Placebo & Rosuvastatin 10mg", 
                    "Telmisartan 80mg & Rosuvastatin placebo", 
                    "Telmisartan placebo & Rosuvastatin placebo"
                ], 
                "intervention_name": "Placebo(for Telmisartan 80mg)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Telmisartan 80mg & Rosuvastatin 10mg", 
                    "Telmisartan Placebo & Rosuvastatin 10mg", 
                    "Telmisartan 80mg & Rosuvastatin placebo", 
                    "Telmisartan placebo & Rosuvastatin placebo"
                ], 
                "intervention_name": "Placebo(for Rosuvastatin 20mg)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Telmisartan 80mg & Rosuvastatin 20mg", 
                    "Telmisartan placebo & Rosuvastatin 20mg", 
                    "Telmisartan placebo & Rosuvastatin placebo"
                ], 
                "intervention_name": "Placebo(for Rosuvastatin 10mg)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Telmisartan", 
                "Rosuvastatin", 
                "Benzoates"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "contact": {
                "email": "chungws@catholic.ac.kr", 
                "last_name": "wook-seong chung, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "The Catholic University of Saint Mary's Hosiptal"
            }, 
            "investigator": {
                "last_name": "wook-seong Chung, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Randomized, Double-blind, Multi-center, Factorial Phase III Clinical Trial to Evaluate the Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "\u2022Change in seated diastolicblood pressure at 8 weeks compared to the base value", 
                "safety_issue": "Yes", 
                "time_frame": "at the 8 weeks"
            }, 
            {
                "measure": "Change in LDL-Cat 8 weeks compared to the base value (% change)", 
                "safety_issue": "Yes", 
                "time_frame": "at the 8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02087540"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in seateddiastolic blood pressure", 
                "safety_issue": "No", 
                "time_frame": "at 2,4 8 weeks"
            }, 
            {
                "measure": "Change in seated systolic blood pressure", 
                "safety_issue": "No", 
                "time_frame": "at 2,4,8weeks"
            }, 
            {
                "measure": "Rate of patients achieving a therapeutic purpose according to JNC VII Guideline [therapeutic purpose for blood pressure: < 140/90 mmHg (however, < 130/80 mmHg for Group III)]", 
                "safety_issue": "No", 
                "time_frame": "at 2, 4 and 8 weeks"
            }, 
            {
                "measure": "Change in LDL-Cat compared to the base value (% change)", 
                "safety_issue": "No", 
                "time_frame": "2, 4 and 8 weeks"
            }, 
            {
                "measure": "Change in TC, TG, HDL-C and Apolipoprotein B compared to the base value (% change)", 
                "safety_issue": "No", 
                "time_frame": "at 2, 4 and 8 weeks"
            }, 
            {
                "measure": "Rate of patients achieving a therapeutic purpose according to NCEP ATP III Guideline therapeutic purpose for LDL-C- (Group I:  < 160 mg/dL, Group II: < 130 mg/dL, Group III: < 100 mg/dL)", 
                "safety_issue": "No", 
                "time_frame": "at 2, 4 and 8 weeks"
            }
        ], 
        "source": "IlDong Pharmaceutical Co Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "IlDong Pharmaceutical Co Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}